Porcine pancreastatin (1.19nmol) was administered into the peripheral vein (i.v.) or the third cerebral ventricle (i.t.v.) of dogs and its effect on the secretion of insulin and pancreatic polypeptide (PP) studied.
Recently Tatemoto et al. (1986) reported the sequence and biological activity of a putative hormone, pancreastatin, from porcine pancreas.
Pancreastatin is a 49-residue peptide, having a glycine amide at its Cterminus.
It inhibits glucose-stimulated insulin release from isolated perfused rat pancreas and from isolated rat islets (Tatemoto et al., 1986; Efendie et al., 1987; Silvestre et al., 1988) and may be important in the regulation of insulin secretion.
Pancreastatin is found in the brain, particularly the pituitary gland (Schmidt et al., 1988; Ravazzola et al., 1988) . This, together with the wide distribution of chromogranin A, a precursor of pancreastatin (Eiden, 1987; Konecki et al., 1987; Huttner et al., 1987; Iacangelo et al., 1988a, b; Helman et al., 1988) in . the brain, indicates that pancreastatin may act on the endocrine pancreas via a neural pathway. The purpose of this study was to examine the effect of pancreastatin administered into the peripheral vein (i.v.) steel cannula was permanently implanted with dental cement, under sodium thiamylal anesthesia, toward the third cerebral ventricle. The methods used have been described elsehwere . The experiments were initiated 2 weeks after the operation. The dogs were fasted for 16 hr before the experiments with free access to tap water.
During each experiment, they were placed in jackets and allowed to remain in a fully conscious, relaxed state.
Experimental design Intravenous butterfly needles were placed in veins in the forelimbs of the dogs, one for infusion of drugs and one for collection of blood samples.
Porcine pancreastatin was prepared as described (Tatemoto et al., 1986) . Synthetic cholecystokinin octapeptide (CCK-8) was kindly donated by Prof. N. Yanaihara (Shizuoka University, Shizuoka, Japan).
Pancreastatin was dissolved in saline and injected i.t.v. (100 pl) or i.v. for 5 min in a single dose of 1.19 nmol. The 1.19 nmol dosage was chosen since many peptides affect visceral and behavioral functions of dogs at this level, including CCK-8 (Morioka et al., 1986; Sakatani et al., 1987; Inui et al., 1988) , corticotropin-releasing factor , neuropeptide Y (Morioka et al., 1986; Inoue et al., 1989; Inui et al., 1989) , and pancreatic polypeptide Inoue et al., 1989) . Experiment 1: Six dogs received an i.v. or i.t.v. injection of pancreastatin or saline vehicle as a control.
Blood samples were obtained during the basal period and between 5 and 120 min after the injection. Experiment 2: Pancreastatin or saline vehicle was i.v. or i.t.v. injected into 5 dogs, followed by an i.v. bolus injection of glucose (0.5 g/kg body wt). Blood samples were obtained during the basal period and at 0 (just after peptide or saline injection), 2.5, 5, 10, 15, 20, 30, 45 , and 60min after the injection of the glucose. Experiment 3: Seven dogs received an i.v. injection of saline first, then pancreastatin 90min later.
Immediately after the peptide or saline injection, CCK-8 was i.v. injected at a dose of 0.8 nmol for 5 min. This dose of CCK-8 was found to cause a significant increase in plasma insulin and PP concentrations via specific CCK receptors (Inui et al., 1988) of the same magnitude as those seen after ingestion of a meal by dogs . The first and second administration of CCK-8 did not make any difference in stimulating insulin and PP secretion (Inui et al.,,,1988) .
Blood was drawn during the basal period and at 0 (just after saline or pancreastatin injection) 5, 10, 15, 20 and 30min after the start of CCK-8 administration.
Laboratory analysis Blood samples (1.8ml) were collected in test tubes containing 400 KIU of aprotinin (TrasylorR, Bayer, Japan) and 1.2mg EDTA in a total volume of 0.2ml.
After centrifugation, plasma aliquots were rapidly frozen for subsequent PP and insulin assays. Blood glucose was assayed by the glucose oxidase method. Plasma PP was measured with a double-antibody radioimmunoassay as previously reported (Mizuno et al., 1979; Inui et al., 1985) . Plasma insulin was measured by a homologous porcine insulin assay using the double antibody separation method. inhibition of basal insulin output from the duodenal lobe of the pancreas in pentobarbital-anesthetized dogs (Dunning et al., 1988 increase in plasma insulin concentrations in conscious mice (Ahren et al., 1988) . Pancreastatin also stimulated basal glucagon secretion and induced a transient hyperglycemia. It was reported that the biological activity of porcine pancreastatin resides in the C-terminal part of the molecule (Tatemoto et al., 1986) which is relatively conserved across the species. However, the structure of porcine pancreastatin has 59-71% homologies to the structures of human, bovine, and rat pancreastatin (Iacangelo et al., 1988b) However, i.t.v. pancrastatin tended to reverse the i.t.v. CCK-8-induced satiety effect (unpublished data), suggesting that the effect of pancreastatin may not be limited to the endocrine pancreas. Thus, further studies are required to evaluate the role of pancreastatin on pancreatic islet functions and other visceral and behavioral functions.
